恒生创新药ETF（159316）持续“吸金”，标的指数今年以来涨超100%

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.4%, with a year-to-date increase of over 100% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 4.0%, while the CSI Innovative Drug Industry Index rose by 3.0% [1] - The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index saw increases of 2.6% and 2.5%, respectively [1] Group 2 - The Hang Seng Innovative Drug ETF (159316) has seen continuous inflows for 10 trading days, reaching a record size of over 800 million yuan [1] - The CSI Biotechnology Theme Index, which focuses on A-share biotechnology leaders, has a rolling price-to-earnings ratio of 59.8 times and has increased by 2.6% [4] - The CSI 300 Pharmaceutical and Health Index, which covers leading companies in the pharmaceutical and health industry, has a rolling price-to-earnings ratio of 31.4 times and has increased by 2.5% [4]